Mechanism and treatment associated with resistance to EGFR-TKI

VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂的耐药机制及应对策略
Author: Qiuyi XU ; Haibo MOU ; Nong XU
Publication Type:Journal Article
Keywords: Cancer,non-small cell lung; Drug therapy; Drug resistance,neoplasm
From: Journal of International Oncology 2012;39(5):355-359
CountryChina
Language:Chinese
Abstract: Epidermal growth factor receptor tyrosine kinases inhibitor (EGFR-TKI) has impressive clinical efficacy in EGFR-mutant non-small cell lung cancer. However,there are still some patients with primary resistance to TKI.And most patients who initially respond to treatment eventually develop resistance to these drugs,which the main molecular mechanisms are T790M and MET amplification.The new targeted therapies and combination drugs to overcome drug resistance is the subject of clinical research.